Page last updated: 2024-10-24

camostat and Cirrhoses, Experimental Liver

camostat has been researched along with Cirrhoses, Experimental Liver in 1 studies

camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.

Research Excerpts

ExcerptRelevanceReference
"Camostat mesilate was either added to cultured rat HSCs or administered orally to rats during porcine serum treatment, followed by overexpression of urokinase."1.31Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. ( Akita, K; Ikeda, K; Kaneda, K; Kawada, N; Kojima, S; Moriwaki, H; Okuno, M; Suzuki, Y, 2001)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Okuno, M1
Akita, K1
Moriwaki, H1
Kawada, N1
Ikeda, K1
Kaneda, K1
Suzuki, Y1
Kojima, S1

Other Studies

1 other study available for camostat and Cirrhoses, Experimental Liver

ArticleYear
Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.
    Gastroenterology, 2001, Volume: 120, Issue:7

    Topics: Animals; Cells, Cultured; Esters; Fibrinolysin; Gabexate; Guanidines; Liver Cirrhosis, Experimental;

2001